The Use of PARP Inhibitors in Cancer Therapy: Use as Adjuvant with Chemotherapy or Radiotherapy, Use as a Single Agent in Susceptible Patients, and Techniques Used to Identify Susceptible Patients.

Abstract

This chapter describes some of the techniques in use in our laboratories for the investigation of PARP inhibitors in clinical medicine. More specifically, we are involved in investigating the utility of PARP inhibitors in the treatment of hematopoietic malignancies. We are also actively investigating the properties of the PARP systems in cell biology. We begin the chapter with a very brief history of the invention and use of PARP inhibitors. We then explain the underlying logic of the use of PARP inhibitors either in combination with chemo- or radiotherapy or as single agents used alone. We then provide in full detail the protocols that we use to study PARP inhibitors in cell biology to identify patients that should be susceptible to PARP inhibitor treatment and to manage and investigate these patients throughout their treatment.

• Authors: Sydney Shall, Terry Gaymes, Farzin Farzaneh, Nicola J Curtin, Ghulam J Mufti
• Journal: Methods in molecular biology (Clifton, N.J.) (Methods Mol Biol) Vol. 1608 Pg. 343-370 ( 2017) ISSN: 1940-6029 [Electronic] United States
• PMID: 28695521 (Publication Type: Journal Article)

Chemical References

• Adjuvants, Pharmaceutic
• Poly(ADP-ribose) Polymerase Inhibitors

Topics

• Adjuvants, Pharmaceutic (therapeutic use)
• DNA Breaks, Single-Stranded (drug effects)
• DNA Repair (drug effects, genetics)
• Humans
• Leukemia (drug therapy, therapy)
• Poly(ADP-ribose) Polymerase Inhibitors (therapeutic use)